Creating the virtual HS multispecialty clinic April 10, 2017 By Lisette Hilton Expert dermatologist describes how to create the virtual multispecialty clinic to address the complex needs of hidradenitis suppurativa. Nonablative technologies and the HS patient April 10, 2017 By Lisette Hilton Nonablative lasers, which are essentially modified hair removal lasers, offer treatment benefits for HS patients with stage 1 or stage 2 disease, according to dermatologist. Combined therapy targets inflammation February 17, 2017 Researchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease.
Further data showed the approach safely maintained results. HS treatment requires multipronged approach February 17, 2017 By Bob Kronemyer Evidence supports combined treatments to target the many factors tied to hidradenitis suppurativa.
See one expert's recommendations. Hidradenitis suppurativa misunderstood and underdiagnosed March 10, 2016 By Lisette Hilton Misconceptions about hidradenitis suppurativa (HS) prevent dermatologists and other clinicians from properly diagnosing and treating what one expert says is a “crippling disease.” Hidradenitis Suppurativa therapy options progressing October 07, 2015 By Ilya Petrou M.D. Many physicians miss diagnosing hidradenitis suppurativa upon first presentation. Recognizing key traits may help physicians diagnose and begin treatment of the disease earlier. TNF Inhibitors Prove Effective April 08, 2015 By Ilya Petrou M.D. TNF inhibitors shown to be effective in improving the clinical symptoms of moderate to severe hidradenitis suppurativa, representing an exciting therapeutic option for this challenging disease. Infection-causing bacteria found in hidradenitis suppurativa lesions November 24, 2014 By Sarah Thuerk Bacteria responsible for causing skin and soft tissue infections has been found in hidradenitis suppurativa lesions, results of a recent study indicate. Early results encouraging in study of adalimumab for hidradenitis suppurativa October 21, 2014 By Bill Gillette New results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug. Algorithm provides quicker diagnosis of hidradenitis suppurativa Hidradenitis suppurativa (HS) is a challenging disease to treat; however, a better understanding of the disease and continued research has led to more clear-cut therapeutic options, according to an expert who spoke at the North American Clinical Dermatologic Society meeting.